Voriconazole use and pharmacokinetics in combination with interferon-gamma for refractory cryptococcal meningitis in a patient receiving low-dose ritonavir.

We present a case of relapsing cryptococcal meningitis unresponsive to standard therapy. Voriconazole induction, including the utilization of voriconazole therapeutic drug monitoring in both serum and CSF, with transition to voriconazole plus interferon-gamma (IFN-gamma) was successfully used in a patient receiving antiretroviral therapy with abacavir/lamivudine and lopinavir/ritonavir. Initial voriconazole levels at standard doses of 4 mg/kg twice daily intravenously were low when co-administered with lopinavir/ritonavir but increased to recommended therapeutic levels with an increase of the voriconazole dose to 7 mg/kg twice daily. This case highlights the utility of voriconazole therapeutic drug monitoring when prescribed concurrently with a ritonavir boosted protease inhibitor and the potential role of combination therapy with IFN-G for refractory cryptococcal meningitis.

[1]  M. Rinaldi,et al.  Posaconazole Therapeutic Drug Monitoring: a Reference Laboratory Experience , 2009, Antimicrobial Agents and Chemotherapy.

[2]  K. Wannemuehler,et al.  Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS , 2009, AIDS.

[3]  B. Wickes,et al.  Antifungal Susceptibilities among Different Serotypes of Cryptococcus gattii and Cryptococcus neoformans , 2008, Antimicrobial Agents and Chemotherapy.

[4]  Thierry Buclin,et al.  Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  Amarnath Sharma,et al.  Steady-State Pharmacokinetic and Safety Profiles of Voriconazole and Ritonavir in Healthy Male Subjects , 2007, Antimicrobial Agents and Chemotherapy.

[6]  L. Gordon,et al.  Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients , 2007, Cancer.

[7]  D. Schaer,et al.  Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring. , 2006, Swiss medical weekly.

[8]  D. Andes,et al.  Voriconazole Therapeutic Drug Monitoring , 2006, Antimicrobial Agents and Chemotherapy.

[9]  N. Wood,et al.  Investigation of the Potential Relationships Between Plasma Voriconazole Concentrations and Visual Adverse Events or Liver Function Test Abnormalities , 2006, Journal of clinical pharmacology.

[10]  E. Thiel,et al.  Improved outcome in central nervous system aspergillosis, using voriconazole treatment. , 2005, Blood.

[11]  P. Pitisuttithum,et al.  Activity of posaconazole in the treatment of central nervous system fungal infections. , 2005, The Journal of antimicrobial chemotherapy.

[12]  M. Pfaller,et al.  Global Trends in the Antifungal Susceptibility of Cryptococcus neoformans (1990 to 2004) , 2005, Journal of Clinical Microbiology.

[13]  E. Ticona,et al.  Recombinant Interferon-γlb as Adjunctive Therapy for AIDS-Related Acute Cryptococcal Meningitis , 2004 .

[14]  S. Roffey,et al.  Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  J. Perfect,et al.  Voriconazole treatment for less-common, emerging, or refractory fungal infections. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  D. Stevens,et al.  Enhancement of antifungal chemotherapy by interferon-gamma in experimental systemic cryptococcosis. , 2000, The Journal of antimicrobial chemotherapy.

[17]  J. Perfect,et al.  Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  E. Anaissie,et al.  Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  D. Stevens,et al.  Combination immunotherapy and antifungal chemotherapy. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  E. Ticona,et al.  Recombinant interferon- gamma 1b as adjunctive therapy for AIDS-related acute cryptococcal meningitis. , 2004, The Journal of infectious diseases.